Literature DB >> 12719321

Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

Richard Long1, Michael Gardam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12719321      PMCID： PMC153687     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  25 in total

1.  Progress in treatment for Crohn's disease.

Authors:  A Brzezinski
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

2.  Biologic therapy for rheumatoid arthritis.

Authors:  J H Klippel
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Infliximab for Crohn's disease: more questions than answers.

Authors:  H J Freeman
Journal:  Can J Gastroenterol       Date:  2001-06       Impact factor: 3.522

4.  Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

Authors:  R N Fedorak
Journal:  Can J Gastroenterol       Date:  2001-06       Impact factor: 3.522

5.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

6.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

7.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 8.  Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.

Authors:  R Panaccione
Journal:  Can J Gastroenterol       Date:  2001-06       Impact factor: 3.522

9.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  W J Sandborn; S B Hanauer; S Katz; M Safdi; D G Wolf; R D Baerg; W J Tremaine; T Johnson; N N Diehl; A R Zinsmeister
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

10.  Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology.

Authors:  V P Mohan; C A Scanga; K Yu; H M Scott; K E Tanaka; E Tsang; M M Tsai; J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441
View more
  17 in total

1.  Infliximab and serious hematologic events.

Authors:  Cynthia Phelan; Eric Wooltorton
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

2.  Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

Authors:  Maria L Olleros; Reto Guler; Dominique Vesin; Roumen Parapanov; Gilles Marchal; Eduardo Martinez-Soria; Nadia Corazza; Jean-Claude Pache; Christoph Mueller; Irene Garcia
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

3.  Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection.

Authors:  Reto Guler; Maria L Olleros; Dominique Vesin; Roumen Parapanov; Irene Garcia
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 4.  The impact of inflammatory bowel disease on oral health.

Authors:  J S Chandan; T Thomas
Journal:  Br Dent J       Date:  2017-04-07       Impact factor: 1.626

5.  Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.

Authors:  Ismail Hanta; Suleyman Ozbek; Sedat Kuleci; Murat Sert; Ali Kocabas
Journal:  Clin Rheumatol       Date:  2007-02-27       Impact factor: 2.980

6.  Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Authors:  Omer Kilic; Ozgur Kasapcopur; Yildiz Camcioglu; Haluk Cokugras; Nil Arisoy; Necla Akcakaya
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

Review 7.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

8.  Preventing tuberculosis in children receiving anti-TNF treatment.

Authors:  Nuray Aktay Ayaz; Erkan Demirkaya; Yelda Bilginer; Uğur Ozçelik; Nazan Cobanoğlu; Nural Kiper; Nesrin Besbas; Aysin Bakkaloğlu; Seza Ozen
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

9.  The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients.

Authors:  Ismail Hanta; Suleyman Ozbek; Sedat Kuleci; Ali Kocabas
Journal:  Clin Rheumatol       Date:  2008-03-05       Impact factor: 2.980

10.  Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests.

Authors:  Saniye Gİrİt; Ayşe Ayzit Atabek; Ebru Şenol; Tuba KoÇkar Kizilirmak; Sevgi Pekcan; Şafak GÖktaŞ; Sedat Öktem; Özgür KasapÇopur; Haluk ÇokuĞraŞ
Journal:  Arch Rheumatol       Date:  2019-06-25       Impact factor: 1.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.